NEU 2.16% $1.13 neuren pharmaceuticals limited


  1. 2,085 Posts.
    lightbulb Created with Sketch. 24

    AIC2015: Showcasing Investment Opportunities in Autism Treatment, Assessment & Technology

    Autism Speaks announces preliminary lineup of presenters for 2015 Autism Investment Conference, March 10-11: Showcase Sessions on autism therapeutics, assessment and assistive technology
    February 09, 2015

    About half way down is:

    Larry Glass, chief executive officer of Neuren Pharmaceuticals, will showcase Neuren’s strategy for developing their lead compound, “NNZ-2566,” for the treatment of neurodevelopmental syndromes. Neuren is developing a number of new treatment for brain disorders and conditions, including autism, Rett syndrome and fragile X syndrome.
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Mkt cap ! $116.0M
Open High Low Value Volume
$1.15 $1.15 $1.13 $68.79K 60.04K

Buyers (Bids)

No. Vol. Price($)
2 2464 $1.13

Sellers (Offers)

Price($) Vol. No.
$1.15 1461 1
View Market Depth
Last update - 15.26pm 19/04/2019 (20 minute delay) ?
-0.025 ( 1.73 %)
Open High Low Volume
$1.15 $1.16 $1.14 9012
Last updated 13.59pm 19/04/2019 (live) ?
NEU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.